Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

Trial Profile

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eflapegrastim (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Pharmacokinetics
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 26 Feb 2021 According to a Spectrum Pharmaceuticals media release, a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS (eflapegrastim) from this trial will be presented as part of the 38th Annual Miami Breast Cancer Conference taking place virtually 4th to 7th Mar 2021.
    • 12 Aug 2020 Results, analysis of data from 3 trails (one phase II and 2 phase III studies) assessing the fixed dose of Eflapegrastim in patients receiving Docetaxel-Cyclophosphamide chemotherapy, published in the Journal of Clinical Pharmacology
    • 27 Dec 2018 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top